The latest in drug and technology developments and updates from August 2025.
What to take away in the worlds of myopia, glaucoma, retina, and dry eye from the past month. Image credit: AdobeStock/Shutter2U
Solutions to combat myopia progression are seeing further growth globally this month with Japan's recent approval of manufacturing and commercial sale of MiSight 1 day soft contact lenses.The lens is now the first and only contact lens approved for myopia control in 3 major markets consisting of Japan, the US, and China. Learn the latest in our roundup of what to take away from the month of August in terms of drug and technology updates below:
CooperVision’s MiSight® 1 day contact lens has gained approval from Japan’s Ministry of Health, Labor, and Welfare for manufacturing and sale in the country.1 This marks MiSight 1 day as the first soft contact lens in the country authorized for use by children to correct myopia and has the potential to control its progression, according to a news release.
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Outlook Therapeutics’ biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD).
Alcon recently announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED), according to a news release.1 The solution was approved by the US Food and Drug Administration in late May 2025 and is packaged in single-dose vials to be administered as 1 drop per eye twice a day.1,2
In recent news from biopharmaceutical company Clearside Biomedical, Health Canada has granted approval of the company’s triamcinolone acetonide injectable suspension (Xipere) for suprachoroidal use in the treatment of uveitic macular edema (UME). Xipere has been approved for use in the US, Canada, Australia, and Singapore, and is under regulatory review in China, according to a news release.1
The first patient has been dosed in Qlaris Bio’s phase 2 Nightingale clinical trial for QLS-111 in patients with normal-tension glaucoma (NTG).1 The study, which is Qlaris Bio’s third phase 2 clinical trial of the company’s lead investigational therapy, will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with NTG and will be conducted at multiple clinical sites across South Korea, according to a news release.
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
